ASMB Files 8-K on Shareholder Vote & Other Events

TL;DR

**ASMB just filed an 8-K about a shareholder vote, signaling potential big changes.**

AI Summary

Assembly Biosciences, Inc. filed an 8-K on February 2, 2024, reporting an event that occurred on January 31, 2024. This filing indicates that the company submitted matters to a vote of security holders and disclosed other events. For investors, this matters because shareholder votes often relate to significant corporate actions like mergers, executive compensation, or changes to company structure, which can directly impact the stock's future performance and shareholder value.

Why It Matters

This filing signals that important corporate decisions are being made or have been made, potentially affecting the company's strategic direction and financial health.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the underlying 'matters submitted to a vote' could carry significant risk or opportunity depending on their nature.

Analyst Insight

A smart investor would monitor subsequent filings from Assembly Biosciences, Inc. for details on the 'matters submitted to a vote of security holders' to understand the implications for the company's future strategy and valuation.

Key Numbers

• 20240131 — Date of earliest event reported (Indicates when the reported event occurred.)
• 001-35005 — Commission File Number (Unique identifier for Assembly Biosciences, Inc. with the SEC.)
• 12 — Public Document Count (Number of documents associated with this filing.)
• 20240202 — Filed As Of Date (The date the 8-K was officially filed with the SEC.)

Key Players & Entities

• Assembly Biosciences, Inc. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Assembly Biosciences, Inc.
• The Nasdaq Global Select Market (company) — exchange where Assembly Biosciences, Inc. common stock is registered
• ASMB (company) — trading symbol for Assembly Biosciences, Inc.
• $0.001 (dollar_amount) — par value of Common Stock

Forward-Looking Statements

• Assembly Biosciences will disclose the specific outcomes of the shareholder vote in a subsequent filing. (Assembly Biosciences, Inc.) — high confidence, target: 2024-03-31

FAQ

From the Filing

0000950170-24-010475.txt : 20240202 0000950170-24-010475.hdr.sgml : 20240202 20240202160510 ACCESSION NUMBER: 0000950170-24-010475 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240131 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Other Events FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 24591324 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 8-K 1 asmb-20240131.htm 8-K 8-K 0001426800 false 0001426800 2024-01-31 2024-01-31     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)       Two Tower Place , 7th Floor , South San Francisco , California 94080 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (833) 509-4583 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001   ASMB   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐         Item 5.07 Submission of Matters to a Vote of Security Holders. On January 31, 2024, Assembly Biosciences, Inc. held a special meeting of stockholders (the "Special Meeting"). The matters listed below were submitted to a vote of the Company's stockholders at the Special Meeting through the solicitation of proxies. Detailed descriptions of each of the proposals are included in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on December 21, 2023.   1. The stockholders approved a series of alternate amendments to the Company's Sixth Amended and Restated Certificate of Incorporat